Cue Biopharma to Host Business Update Call and Webcast

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced a conference call on November 17, 2020, at 4:30 p.m. EST, to update stakeholders on its business progress. The executive team will discuss findings from cohorts 4, 5, and 6 of its ongoing Phase 1 clinical trial of CUE-101, targeting HPV16-driven head and neck cancer. The call will also cover advancements in technology platforms, pipeline updates, and strategic milestones. Access to live and archived versions of the event will be available on the company's website.

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Tuesday, November 17, 2020 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s website.

Members of the Cue Biopharma executive management team will provide a clinical update including details pertaining to patients from cohorts 4, 5 and 6 in the Company’s ongoing Phase 1 monotherapy dose escalation clinical trial of CUE-101 for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Management will also provide an update on the Company’s technology platforms and pipeline progress, as well as updates on its strategic objectives and anticipated milestones.

Tuesday, November 17 at 4:30 p.m. EST
Investors: International: Conference ID: Webcast:	877-407-9208 201-493-6784 13712195 http://public.viavid.com/index.php?id=142111

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com

Media Contact
Alison Chen
LifeSci Communications
achen@lifescicomms.com

FAQ

What will Cue Biopharma discuss in the conference call on November 17, 2020?

The conference call will cover updates on cohorts 4, 5, and 6 from the Phase 1 trial of CUE-101, along with technology and pipeline progress.

What is CUE-101 and its relevance in the clinical trial?

CUE-101 is a treatment aimed at HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma, currently in a Phase 1 clinical trial.

When is the Cue Biopharma conference call scheduled?

The conference call is scheduled for November 17, 2020, at 4:30 p.m. EST.

How can I access the Cue Biopharma conference call?

You can access the conference call live and in archived format via the Cue Biopharma website.

Who are the key speakers in the upcoming Cue Biopharma conference call?

Members of the Cue Biopharma executive management team will provide updates during the call.